Early Patient Access Treatment Use Protocol CA204-220
NCT02856438 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2023-12-19
Summary
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at Japanese sites where licensed physicians determine clinical need.
Conditions
Interventions
- DRUG
-
Elotuzumab
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- Japan
Study Locations
More Related Trials
-
Combination Study for High Risk Multiple Myeloma Patients
NCT03104270 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
NCT02290431 ·Status: COMPLETED ·Phase: PHASE2
-
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
NCT02719613 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
NCT05286229 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01478048 ·Status: COMPLETED ·Phase: PHASE2
-
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT01891643 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
NCT01393964 ·Status: COMPLETED ·Phase: PHASE1
-
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma
NCT01335399 ·Status: COMPLETED ·Phase: PHASE3
-
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
NCT02541643 ·Status: NO_LONGER_AVAILABLE
-
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
NCT02843074 ·Status: COMPLETED ·Phase: PHASE2
-
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT03948035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
NCT03393273 ·Status: WITHDRAWN ·Phase: PHASE2
-
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
NCT03411031 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma
NCT01556438 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
NCT00928486 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
NCT02917941 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
NCT01239797 ·Status: COMPLETED ·Phase: PHASE3
-
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
NCT05981209 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
NCT03361306 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
NCT02612779 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
NCT02918331 ·Status: COMPLETED ·Phase: PHASE1
-
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
NCT02976493 ·Status: COMPLETED
-
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
NCT04150965 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
NCT01632150 ·Status: COMPLETED ·Phase: PHASE2
-
Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma
NCT02666209 ·Status: NO_LONGER_AVAILABLE